Adem Deligonul
Overview
Explore the profile of Adem Deligonul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tunbekici S, Yuksel H, Acar C, Sahin G, Kinikoglu O, Majidova N, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941915
Background/objectives: There is an unmet need to improve outcomes in patients with metastatic Ewing sarcoma (ES). This retrospective, multicenter study aimed to evaluate the efficacy and safety of the topotecan-cyclophosphamide...
2.
Celebi Coskun E, Coskun A, Sahin A, Levent F, Coban E, Koca F, et al.
Front Oncol
. 2025 Jan;
14():1453721.
PMID: 39777349
Background: Immune checkpoint inhibitors (ICI) are generally associated with rare cardiac side effects, yet instances like myocarditis can be fatal. Therefore, detecting and managing left ventricular dysfunction early in ICI...
3.
Ocak B, Sahin A, Erturk I, Korkmaz M, Erdem D, Cakiroglu U, et al.
Curr Oncol
. 2024 Sep;
31(9):5195-5205.
PMID: 39330012
This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular...
4.
Ozsen M, Tolunay S, Senol K, Deligonul A, Gokgoz S, Evrensel T
Turk Patoloji Derg
. 2024 May;
40(3):170-180.
PMID: 38801127
Objective: The tumor microenvironment is a heterogeneous and constantly changing territory that plays an active role in tumor formation and progression. It constantly interacts with tumor cells, plays an active...
5.
Caner B, Orhan S, Deligonul A, Evrensel T
J Cancer Res Ther
. 2024 Mar;
20(1):479-481.
PMID: 38554370
NUT midline carcinoma (NMC) is an aggressive malignant neoplasm arising from midline structures. Although it is classified as a rare disease, the pathological nonspecific appearance as undifferentiated/poorly differentiated carcinoma and...
6.
Ozsen M, Ugras N, Yerci O, Deligonul A, Tasar P, Isik O, et al.
Int J Surg Pathol
. 2024 Feb;
32(7):1256-1262.
PMID: 38332662
Various clinicopathological, radiological, and molecular parameters are predictive of prognosis in patients with colorectal carcinoma and distant organ metastases continue to have a significant place among them. Recent studies reveal...
7.
Ozsen M, Ugras N, Yerci O, Deligonul A
Indian J Pathol Microbiol
. 2023 Dec;
66(4):877-879.
PMID: 38084555
Breast carcinoma is one of the tumors that frequently metastasize to the liver. Extramedullary hematopoiesis (EMH) usually occurs due to insufficient medullary hematopoiesis. In this case report, we present a...
8.
Ozsen M, Tolunay S, Gokgoz M, Deligonul A
Int J Surg Pathol
. 2023 Dec;
32(6):1158-1164.
PMID: 38073094
With <40 case reports published in the English literature, mucinous cystadenocarcinoma of the breast is quite rare compared to its counterparts in the ovary, pancreas, and appendix. The purpose of...
9.
Sahin A, Caner B, Ocak B, Gulmez A, Hamitoglu B, Cubukcu E, et al.
Oncol Lett
. 2023 Nov;
26(6):523.
PMID: 37927419
Thrombocytopenia is a characteristic adverse event of trastuzumab emtansine (T-DM1), one of the essential treatment options for human epithelial growth factor receptor 2 (HER2)-positive breast cancer. The present study investigated...
10.
Sutcuoglu O, Dogan A, Yilmaz F, Sahin A, Sahin T, Akturk Esen S, et al.
Pancreas
. 2023 Oct;
52(4):e235-e240.
PMID: 37816170
Objective: Combination therapies such as FOLFIRINOX or gemcitabine-nanoparticle albumin-bound paclitaxel (GnP) are recommended for the first-line treatment of patients with advanced pancreatic cancer. The purpose of this study was to...